Cis-dichlorodiammineplatinum(II) (cisplatin) is of major importance in the treatment of cancer, particularly ovarian and testicular carcinomas (Loeher and Einhorn, 1984; Wiltshaw and Carr, 1984) . Unfortunately, its value is limited by its toxicity and the frequency with which tumours develop resistance. While the side-effects of cisplatin have been circumvented by the development of carboplatin, both drugs show a similar pattern of resistance in a wide range of tumours (Harrap, 1985; Gore et al., 1989; Mangioni et al., 1989) . The search for a third-generation platinum compound, which does not show cross-reactivity with cisplatin and carboplatin, has led to the development of a series of platinum(IV) ammine/amine dicarboxylates of general structure, c, t, c-[PtC12(OCORI)2NH3(RNH2)] (Harrap et al., 1991a,b; Kelland et al., 1992a) . One of these new compounds [ammine diacetatodichloro (cyclohexylamine)-platinum(IV), JM216], which has been shown to have clinical potential (Kelland et al., 1993) , has recently entered phase II trials.
In human ovarian cell lines, it has been shown that the cytotoxicity could be increased by increasing the number of carbons in the carboxylate ligand (RI); cytotoxicity was also increased by placing an alicyclic group in the amine ligand (Kelland et al., 1992a) . Two of the dicarboxylates [ammine dibutyratodichloro(cyclohexylamine)platinum(IV), JM221; and ammine dibenzoatodichloro(propylamine)platinum(IV), JM244] were capable of overcoming acquired cisplatin resistance, which is caused by decreased intracellular accumulation but were not able to overcome resistance at the level of DNA platination and removal (Kelland et al., 1992b) . The possible value of this class of compound in overcoming cisplatin resistance has been supported by a recent study of 17 ammine/amine Pt(IV) dicarboxylates using the murine leukaemia cell line, L1210, and a cisplatinresistant subline in which it was found that a wide range of these compounds overcame resistance to cisplatin (Orr et al., 1994) .
It is important to learn more about the mechanism of action of the new compounds, particularly in relation to cisplatin. Since attention has recently been focused on the role of apoptosis in drug-induced cytotoxicity Dive and Hickman, 1991; Hickman, 1992) , we have investigated the contribution of apoptosis to cell killing by cisplatin. In a human ovarian carcinoma cell line, CH 1, cisplatin induced apoptosis over the whole dose range studied (Ormerod et al., 1994b) . In L1210 cells, the data were consistent with a dual mechanism of cell death-higher doses of drug led to rapid death through apoptosis; lower doses led to death at later times resulting from a failure to overcome a block in G2 of the cell cycle (Ormerod et al., 1994a) .
As part of our programme of drug development, using the murine leukaemia cell line, L1210, we have undertaken a comparative study of the mechanism of toxic action of four platinum(IV) ammine/amine dicarboxylates, namely, JM216, JM221, ammine diacetatodichloro(propylamine)platinum(IV) (JM223) and JM244 (for structures, see Table I ). These compounds were chosen as representative of the range of compounds of this class, in that the amine contained either an alicyclic (JM216 and JM221) or an alkyl (JM223 and JM244) group and the axial ligand either an aryl (JM244) or an alkyl substituent (JM216, JM221 and JM223). Flow cytometry was used to follow changes in the cell cycle parameters after incubation with drug and to measure the induction of apoptosis.
Materials and methods

Chemicals
The Pt(IV) dicarboxylates were supplied by the Johnson Matthey Technology Centre (Reading, Berks, UK) and the Johnson Matthey Biomedical Research Center (West Chester, PA, USA) (Giandomenico et al., 1991) . Cell culture medium and serum were purchased from ICN Flow (High Wycombe, Bucks, UK), agar noble from Difco Laboratories (Detroit, MI, USA) and all other reagents from Sigma (Poole, Dorset, UK).
Cells and drug treatment The L1210 murine leukaemia cell line was grown as a suspension culture in RPMI-1640 medium supplemented with 10% horse serum, 2 mM L-glutamine and antibiotics (100 U ml-' penicillin and 0.1 mg ml-' streptomycin) (cell doubling time = 14 h). MG Ormerod et at On the Ortho Cytofluorograf, five detectors were available recording, in a forward direction, scattered light and, orthogonally, blue (488 nm, scattered light; or 460 nm, fluorescence), and green (520 nm), orange (570 nm) and red (>630 nm) fluorescences. A similar optical arrangement was used on the Coulter. If the red fluorescence was measuring DNA, then both the peak and the integrated area of the fluorescent signal were recorded and pulse shape analysis was performed to eliminate any cell clumps (Ormerod, 1994) .
For cell cycle analysis, approximately 106 cells were fixed in ice-cold 70% ethanol and stored at 4°C. After washing, cells were resuspended in 800 ,l phosphate-buffered saline (PBS) and 100 ,l propidium iodide (PI) solution (100 Mg ml-') and 100 Ml RNAase solution (1 mg ml-') added before incubation for 2 h at 37°C. The flow cytometer was operated at 488 nm and, after pulse shape analysis and gating on a cytogram of orthogonal vs forward light scatter, either a histogram of cell number against red (DNA-PI) fluorescence or a cytogram of light scatter vs DNA was recorded. Cell cycle analysis was carried out using either our own program (data recorded on the Cytofluorograf; Ormerod et al., 1987) or the MultiCycle program (Phoenix Flow Systems, San Diego, CA, USA) (data recorded on the Elite).
The fraction of apoptotic cells was estimated from the 'sub-GI' peak in the DNA histogram. If apoptotic cells undergo internucleosomal degradation, on fixation, the cells lose low molecular weight DNA and give a peak in the DNA histogram of lower fluorescence than cells in GI of the cell cycle (see, for example, Nicoletti et Darnzynkiewicz et al., 1993) . We have shown previously that apoptotic L1210 cells undergo internucleosomal degradation and produce such a peak in the DNA histogram (Ormerod et al., 1994a) . The fixed apoptotic L1210 cells also had smaller light scatter and the analysis could be improved by setting a region on a cytogram of right angle light scatter vs DNA.
To measure cell cycle progression, 50 ,UM bromodeoxyuridine (BrdUrd) was added to the cultures. Samples were taken at different times, the cells centrifuged and resuspended in ice-cold 100 mM Tris-HCl, 154 mm sodium chloride, 1 mM calcium chloride, 0.5 mM magnesium chloride, 0.1 % (v/v) Nonidet-P40, 0.2% (w/v) bovine serum albumin, 1.2 ,ug ml-' Hoechst 33258, pH 7.4; PI was added to a final concentration of 2 ,ug ml- (Poot and Ormerod, 1994) . UV radiation was used for the flow cytometric analysis, which was performed on the Ortho Cytofluorograf. After gating on a cytogram of peak vs area of the red fluorescent (PI-DNA) signal, a cytogram of red vs blue (Hoechst-DNA) fluorescence was recorded.
Results
Cell survival
The survival of L1210 cells, as measured in a soft agar colony assay, after incubation with the four compounds for 2 h is shown in Figure 1 . The values of the IC50s together with the structures of the compounds are given in Table I . The concentration of drug needed to achieve the same level of cytotoxicity varied by a factor of 100-JM216 requiring the most drug, JM244 the least.
Platinum uptake and platination of DNA Table II shows the amount of platinum associated with DNA and with the cells after a 2 h incubation with the four drugs at 10 x IC50. There was significantly more Pt bound to DNA after treatment with JM216 compared with JM244 but the difference, which was reflected in the amount of intracellular Pt, was less than 3-fold. There was a smaller, but also significant, difference between JM216 and JM221.
Cell cycle analysis offixed cells After a 2 h incubation with the four compounds, cells were collected at different times, fixed in ethanol, stained with PI and their DNA histograms analysed (Figure 2 ). At 10 x IC50, by 6 h after treatment with JM216, there was substantial apoptosis, the apoptotic cells giving a cluster with less DNA ('sub-GI' peak) and lower light scatter. Although apoptosis could be detected after incubation with 10 x IC50 of other drugs, there were significantly less apoptotic cells present (Figure 3 ). For all four drugs, at 3 x IC50, no apoptosis could be detected (Figure 3 fraction in each phase of the cell cycle vs time (Figure 4) . By 24 h, the arrested cells showed increased light scatter, presumably caused by an increase in cell size, as has been observed after incubation with cisplatin (Sorenson et al., 1990; Ormerod et al., 1994a) . By 48 h, cycling cells of normal light scatter were again evident. The cell cycle effects after incubation with the drugs at 3 x IC50 were similar, but less marked, to those at 10 x IC50 (data not shown). (Rabinovitch et al., 1988) . A detailed h JM216 (0) description of the application of this method to asynchronous or JM216 (x) cells has been given by Ormerod and Kubbies (1992), Poot )tained from the and Ormerod (1994) and Ormerod (1994) . some had progressed as far as G2/M (G2f) and divided again (marked GI). Cells which had begun the experiment in Sphase and had now reached GI are labelled GI.. At 9 h, there were few cells which had not left GI. Cells which had completed one cycle (G,) were clearly visible. The effects of incubation with drug are illustrated at three time points for JM244 at 10 x IC50 and 3 x IC50 (Figure 6 ). Three hours after incubation with both doses of drug, the major effect observed was a slowdown in movement of cells through S-phase, while most of the cells in G2/M at the time of treatment had divided. At 6 h, after 3 x IC50, some cells from late S-phase had progressed back to GI (9% of the total); cells treated in mid and early S-phase were held up in late S/G2. By 9 h, most of the cells which had been in G, and G2/M at time 0 had progressed into S (Se), some had reached G2 and become blocked there (G2t). Most and late S-phase had overcome any G2 block and divided. (Cells treated in S-phase, which had become blocked in G2, would have been to the right of the position marked G2* in Figure 6 ). After 10 x IC50, the same pattern was observed, but the general slowdown in cell cycle progression was even more marked. After 9 h, cells from G1 and early S had still to reach G2.
Incubation with the other drugs at 3 x and 10 x IC50 gave similar results, except that apoptotic cells were evident after the higher concentration of drug (Figure 7) . The number of apoptotic cells observed was greatest with JM216 and least with JM244.
The BrdUrd-Hoechst/PI method was also used to explore the fate of cells, which became blocked in G2 (Figure 8 ). Cells were incubated with 10 x IC50 JM221 for 2 h, washed, and either BrdUrd was added immediately or they were incubated for a further 24 h, when BrdUrd was added. Incubation with BrdUrd for 24 h showed that the large majority of the cells in G2 were cells that had been exposed to the drug in GI or G2/ M of the cell cycle (G2f in Figure 8) . Most of the cells in G, had divided during the previous 24 h (G1 ). Addition of BrdUrd 24 h after incubation with drug showed that there were two populations of cells, one cycling normally, the other blocked in G2 and disappearing from the culture. The in S-phase at the time of addition of BrdUrd; Sf, cells which were initially in GI and had moved into S-phase; G., cells which were initially in S-phase and had divided and were in GI; G1, cells which were initially in G, and had cycled through to G, after addition of BrdUrd and S and G2 are cells in their second cycle. The numbers on the cytograms give the time in h after addition of BrdUrd. Discussion A major feature of the survival data in Figure 1 was the large differences in the concentration of drug needed to achieve the same level of cytotoxicity. JM216 was used at 100 times the concentration of JM244 with JM221 and JM223 lying in between. A large part of the differences would have been caused by differential uptake of the drugs by cells and by the same for the four drugs (about 10), so that the rank order held whichever measurement was used.
At doses of drug of 3 x IC50 for all four drugs or at 10 x IC50 for JM221, JM223 or JM244, the effects on the cell cycle were similar to those observed with cisplatin (Sorenson and Eastman, 1988a,b; Sorenson et al., 1990; Demarq et al., 1992; Fujikane et al., 1989; Ormerod et al., 1994a) . Initially, there was a slowdown in transit through S-phase followed by a G2 block. This conclusion can be drawn from both the DNA histograms and the data acquired after incubation with BrdUrd ( Figure 6 ). The cells blocked in G2 enlarged (as evidenced by their increased light scatter, Figure 2 ) before eventually dying.
From our previous work, we have concluded that there are two mechanisms whereby cisplatin kills cells (Ormerod et al., 1994a (Ormerod et al., ,b, 1996 . The earlier mechanism is apoptosis, which is probably triggered while the cells are held up in S-phase. If cells complete S-phase and if they fail to overcome the block in G2, they die in the blocked G2 stage of the cell cycle, probably by a non-apoptotic mechanism. In human ovarian carcinoma cells, apoptosis predominated at doses of drug > 3 x IC,o (Ormerod et al., 1994b (Ormerod et al., , 1996 , whereas, in L1210 cells, apoptosis was only observed at doses of drug > 15 x IC50 (Ormerod et al., 1994a) .
The same mechanisms were observed in this study. With a sufficiently high dose of any of the four drugs, apoptosis was observed after 4 -12 h. However, at equitoxic doses, the number of apoptotic cells observed was ranked JM216 > JM221 -JM223 > JM244; this was the same ranking as the amount of Pt bound to the DNA. The induction of apoptosis seemed to be related to the amount of damage to DNA. The inability to overcome a G2 block might be more closely related to the type of lesion.
While there have been several studies of the lesions caused by the reaction of cisplatin with DNA (for example, see Roberts and Friedlos, 1987; Eastman, 1987) , little is known about the reaction of the Pt(IV) dicarboxylates with the DNA in cells. Indeed, it is probable that the metabolites of these drugs react with the DNA rather than the parent compound (Kelland et al., 1992) . For example, it appears that iproplatin, cis -dichloro -trans -dihydroxo -cis-bis(isopropylamine)Pt(IV), undergoes reduction to a Pt(II) metabolite before reacting with DNA in cells (Pendyala et al., 1990) . In cultured human ovarian carcinoma cells, metabolites of JM216 include JM 1 18 -cis-ammine dichloro (cyclohexylamine) Pt (II), JM338 -bis-acetato ammine (cyclohexylamine) dihydroxo Pt (IV) -and a glutathione adduct (Raynaud et al., 1996) .
From our data, it would appear that JM244 is more effective than JM216 in creating lesions on the DNA, which block the cell in G2 of the cell cycle. At doses of drug < 15 x IC50, this effect predominated. In contrast, because the lesions created by JM216 were less effective at blocking the cells in G2, at an equitoxic dose, sufficient DNA damage accumulated to trigger apoptosis.
It would be interesting to study the effect of these drugs on the human ovarian cell line, CH1. Cisplatin triggers apoptosis in these cells at doses > 3 x IC50. A comparative study of JM216 and JM244 might reveal whether these cells are more sensitive to the induction of apoptosis than L1210 cells or whether they are more resistant to a G2 block.
Recently, attention has been focused on the role of apoptosis in drug-induced cytotoxicty. The data presented in this paper, taken together with our earlier data (Ormerod et al., 1994a (Ormerod et al., ,b, 1996 , suggest that, when mechanisms of resistance are studied, other cytotoxic mechanisms should also be taken into account. 
